Breaking News Instant updates and real-time market news.

NKTR

Nektar

$34.06

-1.24 (-3.51%)

08:55
11/10/18
11/10
08:55
11/10/18
08:55

Nektar to hold a conference call

Dr. Harriet Kluger of Yale Cancer Center and Dr. Diab of Anderson Cancer Center discuss their presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting on a conference call to be held on November 10 at 9 am. Webcast Link

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 27

    Nov

NKTR Nektar
$34.06

-1.24 (-3.51%)

11/08/18
HCWC
11/08/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar shares may have bottomed, says H.C. Wainwright
During last night's Q3 corporate update call, Nektar Therapeutics provided clarity on soon to be initiated Phase 3 programs, with a vital expansion cohort in second line non-small cell lung cancer, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. While the renal cell carcinoma, bladder, and melanoma studies were telegraphed previously, "clarity was welcome news for the bulls," says Chattopadhyay. However, the analyst adds that RCC and melanoma remain very crowded and that the initiation of triplet studies, if successfully clinically, "would significantly add to the financial toxicity discussion, especially since NKTR-214 is likely to be marketed as a unique medicine." Chattopadhyay thinks the newly defined cohort of approximately 100 second-line NSCLC patients to the ongoing Pivot trial is key to sentiment around the NKTR-214 story during the second half of 2019. He attributes the recent pullback in Nektar shares to disappointment from the preliminary read from the SITC abstract. Nonetheless, with a host of trial initiations and multiple combination updates at disease specific conferences during 2019, the stock may have bottomed, Chattopadhyay writes. However, the analyst says that while the study initiations and data releases should "quell some fears," the data quality "needs a pickup." He keeps a Neutral rating on Nektar with a $47 price target.
11/08/18
JEFF
11/08/18
NO CHANGE
Target $73
JEFF
Buy
Nektar price target lowered to $73 from $103 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Nektar Therapeutics (NKTR) to $73 after reducing his assumptions for NKTR-214 to reflect a potentially prolonged delay in non-small-cell lung carcinoma. The analyst, however, keeps a Buy rating on the shares following the company's Q3 results. He points out that Nektar's partnership with Bristol-Myers (BMY) as well as its other collaborations are ramping up.
11/06/18
PIPR
11/06/18
NO CHANGE
PIPR
Nektar abstract references old 50% ORR, says Piper Jaffray
The regular Society for Immunotherapy of Cancer abstract that provides an update of the first line melanoma patient cohort in the ongoing PIVOT-02 trial testing the combination of Nektar Therapeutics's NKTR-214 plus Opdivo was posted, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that 41 patients were enrolled with 38 evaluable for efficacy and the investigator-assessed objective response rate as of July 12 was 50%. Van Buren says that while is this is what we already knew, it confirms his prior assumption of the 50% response rate floor heading into the Friday afternoon updated data presentation. On Friday, the analyst expects to receive an updated response rate and more details on the quality of response. Finally, no responder has relapsed in this cohort and median duration of response has not been reached, which is promising as we begin to think about the probability of success for the Phase III trial, says the analyst. Shares of Nektar are down 7%, or $2.75, to $37.25 in pre-market trading.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/18
11/20
12:17
11/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/18
11/20
12:16
11/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$34.13

-1.16 (-3.29%)

12:10
11/20/18
11/20
12:10
11/20/18
12:10
Options
Puts lead calls 4:1 in Boston Scientific as implied volatilities lift »

Puts lead calls 4:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

12:10
11/20/18
11/20
12:10
11/20/18
12:10
General news
U.S. equities remain under pressure »

U.S. equities remain…

AMAT

Applied Materials

$36.27

1.85 (5.37%)

12:05
11/20/18
11/20
12:05
11/20/18
12:05
Options
Applied Materials call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/20/18
11/20
12:05
11/20/18
12:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

FB

Facebook

$133.04

1.42 (1.08%)

12:02
11/20/18
11/20
12:02
11/20/18
12:02
Hot Stocks
Facebook experiencing service issues »

Visiting Facebook.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EGRX

Eagle Pharmaceuticals

$48.01

-1.36 (-2.75%)

12:01
11/20/18
11/20
12:01
11/20/18
12:01
Conference/Events
Eagle Pharmaceuticals management to meet with RBC Capital »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 02

    Dec

SDRL

Seadrill

$14.63

-1.84 (-11.17%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Seadrill falls -11.2% »

Seadrill is down -11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EROS

Eros International

$8.19

-1.16 (-12.41%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Eros International falls -12.4% »

Eros International is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 20

    Dec

LB

L Brands

$30.23

-4.3 (-12.45%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
L Brands falls -12.5% »

L Brands is down -12.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SCO

Scor ADR

$23.44

2.26 (10.67%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Scor ADR rises 10.9% »

Scor ADR is up 10.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$45.61

4.81 (11.79%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Noah Holdings rises 11.3% »

Noah Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$11.85

1.62 (15.84%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Britannia Bulk rises 16.1% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$28.44

0.7 (2.52%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX raises FY19 revenue view to $38.6B-$38.7B from $38.2B-$38.4B »

Consensus $38.44B. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX sees Q4 revenue $10B-$10.9B, consensus $10.92B »

Says guidance assumes a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

UNP

Union Pacific

$142.91

-7.74 (-5.14%)

11:55
11/20/18
11/20
11:55
11/20/18
11:55
Options
Union Pacific put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

11:53
11/20/18
11/20
11:53
11/20/18
11:53
Conference/Events
William Blair industrial technology analysts to hold a group luncheon »

Group Luncheon Meeting to…

BECN

Beacon Roofing

$28.34

0.6 (2.16%)

11:52
11/20/18
11/20
11:52
11/20/18
11:52
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:51
11/20/18
11/20
11:51
11/20/18
11:51
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
General news
U.S. sold $50 B 4-week T-bills at a 2.20% high rate »

U.S. sold $50 B 4-week…

11:43
11/20/18
11/20
11:43
11/20/18
11:43
Conference/Events
William Blair industrials & business services analysts hold dinner meeting »

Analysts hold a year-end…

BBY

Best Buy

$63.57

1.38 (2.22%)

11:42
11/20/18
11/20
11:42
11/20/18
11:42
Recommendations
Best Buy analyst commentary  »

Best Buy 'continued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.